Genome engineering, which manipulates DNA in unprecedented ways, can be seen as part of the genuine human (ad)venture-as a quest to change the future. In medicine, it has been only in the last century or so that we are in (partial) control. Before the 1930s, almost all doctors could do was provide palliation and placebo. The arrival of antibiotics and other drugs gave physicians options that provided logic and predictability to interventions in several groups of human disease. As the role of science in medicine increased, each fundamental discovery led to more insight and more control. Chief among these discoveries was the understanding of DNA's structure, cloning, and sequencing. Before the era of DNA, genes were seen as messengers of inherited characteristics (Mendel, and blueprints of cellular function (Schrö dinger, mid20th century) that seemingly doomed us to a predetermined and immutable fate. Now genes have become something that can be made, tinkered with, and changed. Once researchers had the blueprint of our existence, they had the ability to engineer unheard-of changes to our future.
The tools to manipulate our genes have evolved from DNA sequencecomplementary oligonucleotides and self-splicing introns, through viralmediated transgenesis, and now into site-specific DNA-protein recognition of nucleases. These new technologies include zinc finger nuclease, transcription activator-like effector nuclease (TALEN), the clustered regularlyinterspaced palindromic repeats (CRISPR)/CRISPR-associated (Cas) system, and meganuclease, the last featured in the report by Izmiryan et al. (2016) , which describes work performed by the group of Alain Hovnanian in Paris, France. Indeed, designer nucleases are attracting a lot of attention-Science magazine chose TALENs as one of 2012's breakthrough runners-up (Breakthrough of the year. The runners-up, 2012) and CRISPR as the breakthrough of 2015 (Travis, 2015) -yielding access to the "sealed treasure" of our genome. With the ability to reprogram genetic information, make foundational changes in the understanding and treatment of human disease, and invent a new system of reference and practical ethics in medicine, we have the tools in the toolbox for determining our future.
The French connection
Discovery of meganucleases started with experiments done almost half a century ago-and only a 10-minute walk from Professor Hovnanian's current laboratory. It was there, in the Pasteur Institute, that the group of Piotr Słonimski observed (with surprise, because there was no precedent for the various roles of introns) that an intronic DNA of a yeast mitochondrial allele (termed I-SceI or omega) contained a functional gene that was laterally inherited (Bolotin et al., 1971) . This gene was a DNA endonuclease with the ability to invade genomic loci by homing to them, cutting the DNA, and inserting itself into the site of the double-stranded break it had created. These mobile elements (there are at least 5 types distinguished by conserved amino acid motifs) were therefore termed "homing endonucleases." They are also called "meganucleases" (Belfort and Bonocora, 2014) because their DNA recognition sites are longer than the recognition sites of typical restriction enzymes (14e40 base pairs vs. 4e8 base pairs). Typically several hundred amino acids in size and less stringent in DNA recognition sequences compared with typical restriction enzymes, meganucleases are able to home to new genomic sites. The largest class of meganucleases/homing endonucleases is the group of LAGLIDADG homing endonucleases (LHEs), which is characterized by 1 or 2 conserved amino acid motifs, or LAGLIDADG sequences. In the current work, the group of Professor Hovnanian used I-CreI-derived single-chain LHE meganucleases to genetically edit two disease-causing mutations in a prototypical human genodermatosis, recessive dystrophic epidermolysis bullosa (RDEB). This work is a continuation of his lifelong quest to better understand and to ameliorate the suffering associated with this grave and formidable disease.
Skin fragility
RDEB is caused by mutations in the gene encoding C7 (COL7A1) on chromosome 3p21.3, which results in abnormal or absent anchoring fibrils. Type VII collagen (C7) that homopolymerizes at the dermal-epidermal junction and forms the main component of anchoring fibrils-via interlacing with interstitial collagen fibers-makes the attachment of the cutaneous basement-membrane to the papillary dermis possible. Because of biallelic loss-of-function COL7A1 mutations, patients with RDEB have severe skin blistering (Figure 1 ) , increased risk of local and systemic infections, nail dystrophy, and corneal erosions. Oral and esophageal mucosal wounds lead to strictures that make normal eating impossible, chronic blood loss results in anemia, and there is an overall failure to thrive. Wounds are unceasing, and the associated inflammatory response and ineffective tissue repair lead to pseudosyndactyly, mutilating scarring, and a predisposition for aggressive, lethal squamous cell carcinomas.
Proof of concept
To increase future options in this grim clinical situation, Izmiryan et al. (2016) have provided evidence that I-CreIderived single-chain LHE meganucleases can restore C7 expression in unselected human primary RDEB cells. They used integration-deficient lentiviral vectors for delivery of LHE meganucleases, the expression of which was controlled by elongation factor 1 promoter. (Cytomegalovirus promotercontrolled expression of LHE meganucleases was not adequate). They first assessed the targeting efficacy of LHE meganucleases-as evidenced by the double-stranded break induced at the desired DNA site (in the vicinity of the 2 chosen COL7A1 mutations, 1 with 302 base pairs and 1 with 630 base pairs)-by engaging the error-prone DNA repair mechanism called "non-homologous end joining," through which insertions and deletions are introduced at the site of a nuclease-mediated double-stranded break. Because homology-directed repair is needed to achieve gene correction, in the next step a donor DNA sequence complementary to the targeted region (wild-type repair template) was co-transduced with increasing doses of LHE meganucleases. After optimization, corrected COL7A1 transcription (by allele-specific PCR) was detected in 1.8% of primary RDEB fibroblasts and 4% of primary RDEB keratinocytes, which correlated with restoration of C7 protein expression in approximately 1 in 20 cells examined. No genomic off-target activity of LHE meganucleases was found in 10 potential genomic sites (identified by alignment of the endogenous LHE meganuclease recognition sites with the reference human genome), and integration-deficient lentiviral vectors did not compromise cellular viability.
Work of others
The COL7A1 mutations in human RDEB cells have been genetically edited with TALENs (Osborn et al., 2013) and by using recombinogenic species of adeno-associated virus (Sebastiano et al., 2014) . LHE meganuclease-mediated correction has been accomplished in RAG1 (for severe combined immune deficiency), XPC1 (for xeroderma pigmentosum), and dystrophin (for Duchenne's muscular dystrophy) genes, which in principle corrected the disease-causing mutations (Chapdelaine et al., 2010; Munoz et al., 2011; Redondo et al., 2008) . With a number of options available for gene editing (including hybrid species) and the inevitable bias of researchers to overestimate the efficacy of a technology they know or have pioneered, it is critical to compare different nucleases at the same locus. To our knowledge such true comparison has been done only recently-among TALENs, CRISPR/Cas9, and a fusion of a meganuclease to transcription activatorlike (TAL) repeats (megaTAL)-and suggests that megaTAL and CRISPR/ Cas9 are superior to TALENs for a single specific gene (Osborn et al., 2015) . 
Clinical Implications
Gene editing provides a novel approach to gene therapy of human genodermatoses. Beyond gene editing of disease-causing mutations, custom-made nucleases may enable regulation of disease-modifying factors. Technology exists to engineer highly specialized "neo-cells" to target polyfunctional regulation of disease-associated pathways.
www.jidonline.org 743
Something borrowed
To see where this technology can lead, we could reframe this work within the enormous versatility of synthetic molecular biology-for example, for the possibility that nucleases can be used not just for gene editing but also for gene regulation. The cells that are modified by them can be instructed to perform specific tasks. This repurposing of nature is a common theme for nontraditional "venture" science and for predicting (correctly) what comes next in the best biotechnology applications: antibiotics and CRISPR/Cas9 have been "borrowed" from bacteria, TALENs from plants, and LHE meganucleases from bacteria and yeast. All of these ideas are hybrids, partly physiological (in one setting) and partly artificial (in another). Their clinically actionable potential is a continuum spanning the hierarchy of systems of gene/cell/tissue/organism/population, where an insight at one level of organization (e.g., innate immune system of bacteria) can be the emerging property of another (e.g., cell fate determination by "dead" Cas9 paired with a single guide RNA in a mammalian cell). As we learn from challenges and change, and as we recombine and hybridize not just the genes but also ideas, there is more to think about, for example . . .
RDEB is not a single gene disease
Of course, RDEB starts with mutations in a single gene, COL7A1. Nevertheless, by the time a clinician is called to intervene, the disease cascade of changes in other mucocutaneous cellular and matrix components, local and systemic inflammation, and fibrosis have typically been established. Because these processes frequently represent the bulk of the clinical burden, the simple correction of COL7A1 mutations may not fully reverse the disease phenotype.
In many compensatory and maladaptive ways, the RDEB phenotype changes with time and can be seen as different diseases at birth, in childhood, and in adult life. The progressive nature of the evolution of such a disease is similar to a spreading flame, where extinguishing the initiating spark does not mitigate its subsequent effects. Because our goal is the restoration of health, not just the amelioration of the signs and symptoms of RDEB, we will want to explore the additional capacities offered by gene editing. We could, for example, not only rewrite the COL7A1 mutations to restore C7 production but also apply customizable nucleases as gene regulators (Figure 2) . It is plausible that gene-corrective and gene-regulatory modules could be combined in multifunctional CRISPR/Cas9-based designer molecules that would address the comprehensive pathology of RDEB as it extends far outside the loss-of-function COL7A1 mutations that initiate the disease process.
RNA-guided DNA-specific gene regulators
For example, one can use a variant of Cas9 (termed dCas9) with mutations in the HNH and RuvC-like domains that inactivate its nuclease function and yield an RNA-guided DNA-binding protein.
In this fashion, dCas9 enables regulation of transcription without a permanent change in the gene sequence. To repress the RDEB disease cascade effectors that amplify the initial COL7A1 genetic insult, CRISPR interference can be accomplished by transfection of single guide RNA that enables the CRISPR complex to bind a gene-specific sequence and block RNA polymerase (and thus the transcription elongation process). To activate effectors with the capacity to ameliorate the disease process, activation domain-dCas9 fusion (e.g., VP64) can be used. It may be even possible to design a comprehensive RDEB-specific treatment system, where simultaneous gene correction, activation, and repression are performed by scaffold RNAs, and the single guide RNA sequences are functionally amplified by protein-binding RNA aptamers to simultaneously target the desired sequences and recruit specific activators or repressors. The added benefits of these sequence-specific, nuclease-null gene regulatory tools are (i) the capacity to include, in principle, any additional genes; (ii) the transient nature of their regulation (i.e., reversibility); and (iii) the possibility that they can be induced (e.g., by heterodimerization after exposure to blue light). The transient and inducible expression can be used to further finetune the levels of expression of these genes, thus making this a modular technology that can be tailored to individual patients as part of an overall vision for precision medicine for RDEB (Figure 2 ).
Gene-modified cells, "neo-cells," as medicine Cells have phenomenal qualities. They receive and process information; they understand their environment, space, and time; and they can be programmed in a transistor-like fashion to react to certain conditions. Customizable nucleases, with unmatched diversity and specificity can be deployed to precise targets, and-when paired with equally advanced expertise in stem cell biology and transplantation biology-we now have the technology to engineer highly specialized, designer cells ("neo-cells," entirely new to nature) to target polyfunctional regulation of diseaseassociated pathways, such as in RDEB. The resource of gene editing, however well intentioned in its origins, can be diverted to ill purposes and therefore comes with responsibility. For example, although it is possible to edit genes in a human zygote-is it the right thing to do? In December 2015, leading scientists at the International Summit on Human Gene Editing (Committee on Science, Technology, and Law, et al., 2016) concluded that the current gene editing technology is not yet ready for genome engineering of human embryos intended for gravidity. Thus, we need to seek a civilized optimum of this new technology and develop the ability to bring these therapies to the clinic in a way that is ethical, safe (leaving no foreign DNA behind), and combinatorial (Tolar and Wagner, 2015) . As for most patients alive today, the only clinical intervention that matters is one that can be available soon. Biotechnology has to merge with biomedicine quickly. Thankfully, custom-made nucleases for genome engineering have the momentum to accomplish exactly that.
